Sign In
Last checked at 
16 May 2018 13:30
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 30 April 2018
Net Assets | £217m |
Net Assets per share | 579p |
Share price | 556p |
Total value of unquoted investments | £23m |
Total number of portfolio companies | 90 |
Dividend | 4% of NAV per annum |
Top Ten Quoted Investments
Company Name | % NAV |
Celgene | 6.0 |
Neurocrine | 4.2 |
Biogen | 4.2 |
Array | 3.9 |
Sage | 3.8 |
Genmab | 3.8 |
Adamas | 3.7 |
Regeneron | 3.7 |
Morphosys | 3.7 |
Vertex | 3.5 |
----------- | |
Total | 40.5 |
Geographical Allocation | % NAV |
US & Canada | 86 |
Europe & UK | 14 |
----------- | |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 91 |
Unquoted | 9 |
----------- | |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 35 |
Mid Cap =USD1-10BN | 40 |
Small Cap | 25 |
----------- | |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 41 |
CNS | 15 |
Rare diseases | 12 |
Inflammation | 6 |
Ophthalmology | 6 |
Infectious Diseases | 4 |
Metabolic | 3 |
Medtech | 2 |
Other | 11 |
----------- | |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
16 MAY 2018
Follow the stocks
